Drug intelligence / Profile preview

ATS-8535

Development stage: Discontinued
Lead developer: Altheos
Modality: Small Molecules
Administration: Topical

Overview

**ATS-8535** is a selective small molecule inhibitor of Rho-associated coiled-coil containing protein kinase (ROCK), developed by Asahi Kasei Corp. and advanced by Altheos, Inc. as an eye drop for lowering intraocular pressure (IOP) in glaucoma and ocular hypertension. It promotes trabecular meshwork relaxation and aqueous humor outflow, offering potential as a next-generation antiglaucoma agent with demonstrated IOP reduction in preclinical models.[4][10][13][16]

Other names: ATS-8535ATS8535ATS 8535

Targets

ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on ATS-8535.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATS-8535.

Explore the full profile